I agree there’s something strange about Loyal’s strategy.
But it’s not like all aging researchers act like they back Loyal’s approach. Intervene Immune has been getting good biomarker results in human trials by taking nearly the opposite approach: raising IGF-1 levels for a while.
I wrote a longer discussion about IGF-1 and aging in my review of Morgan Levine’s book True Age.
I agree there’s something strange about Loyal’s strategy.
But it’s not like all aging researchers act like they back Loyal’s approach. Intervene Immune has been getting good biomarker results in human trials by taking nearly the opposite approach: raising IGF-1 levels for a while.
I wrote a longer discussion about IGF-1 and aging in my review of Morgan Levine’s book True Age.